Suppr超能文献

腺嘌呤免疫抑制机制的研究。

Studies on the mechanism of immunosuppression with adenine.

作者信息

Chalmers A H, Rotstein T, Mohan Rao M, Marshall V R, Coleman M

出版信息

Int J Immunopharmacol. 1985;7(4):433-42. doi: 10.1016/0192-0561(85)90061-x.

Abstract

Studies on the mechanism of immunosuppression shown by adenine comprised two areas: (1) Toxicity studies on hepatic, muscle and renal tissues were undertaken to ascertain if immunosuppression was a result of a non specific toxicity. (2) Studies to determine whether immunosuppression is a function of the inhibitory effect on de novo and salvage pathways of purine nucleotide metabolism. Toxicity studies in mice indicated that adenine caused an acute, reversible renal tubular necrosis and that allopurinol, when combined with adenine, could abrogate both the renal toxicity and immunosuppressive activity of the purine base. This result indicated that the toxic and/or immunosuppressive compound may be a xanthine oxidase catalysed product of adenine. Further studies indicated that it was unlikely that a major part of the immunosuppressive activity of adenine was due to the renal toxicity exerted by this compound. Splenic PRPP levels were found to peak on day 4 after antigen administration (day 0) and this corresponded with the peak in antibody plaque response which occurred at day 4 to 5. Adenine given at an immunosuppressive dose of 25 mumoles/mouse on day 0, 1 resulted in a significant inhibition of splenic PRPP levels on day 2 of the response. This effect on splenic PRPP levels on day 2 was also found with hypoxanthine given at an immune enhancing dose and therefore would indicate that depression of splenic PRPP per se is not responsible for the immunosuppression. Adenosine given at immunosuppressive doses was found not to affect PRPP levels in the spleen and hepatic PRPP levels were unaffected by adenine, adenosine and hypoxanthine. The in vivo effects of adenine on hypoxanthine-guanine phosphoribosyltransferase showed that adenine could inhibit significantly this salvage pathway in spleen and liver and that this inhibition could be overcome with concomitant administration of allopurinol. A metabolite of adenine which could contribute to its immunosuppressive activity may be 2-hydroxyadenine since it is derived from the xanthine oxidase catalysed oxidation of adenine inhibited hypoxanthine-guanine phosphoribosyltransferase gave similar renal toxicity to adenine and was immunosuppressive.

摘要

对腺嘌呤所致免疫抑制机制的研究包括两个方面

(1) 对肝脏、肌肉和肾脏组织进行毒性研究,以确定免疫抑制是否是由非特异性毒性导致的。(2) 开展研究以确定免疫抑制是否是对嘌呤核苷酸代谢的从头合成途径和补救途径产生抑制作用的结果。对小鼠的毒性研究表明,腺嘌呤可引起急性、可逆性肾小管坏死,并且当别嘌呤醇与腺嘌呤联合使用时,可消除嘌呤碱的肾毒性和免疫抑制活性。这一结果表明,有毒和/或免疫抑制性化合物可能是腺嘌呤经黄嘌呤氧化酶催化产生的产物。进一步研究表明,腺嘌呤免疫抑制活性的主要部分不太可能是由该化合物所产生的肾毒性导致的。在抗原给药(第0天)后第4天,脾脏磷酸核糖焦磷酸(PRPP)水平达到峰值,这与在第4至5天出现的抗体空斑反应峰值相对应。在第0天、第1天以25微摩尔/小鼠的免疫抑制剂量给予腺嘌呤,可导致在反应的第2天脾脏PRPP水平受到显著抑制。以免疫增强剂量给予次黄嘌呤时,在第2天也发现了对脾脏PRPP水平的这种影响,因此这表明脾脏PRPP本身的降低并非免疫抑制的原因。以免疫抑制剂量给予腺苷时,发现其不影响脾脏中的PRPP水平,并且腺嘌呤、腺苷和次黄嘌呤均不影响肝脏中的PRPP水平。腺嘌呤对次黄嘌呤 - 鸟嘌呤磷酸核糖转移酶的体内作用表明,腺嘌呤可显著抑制脾脏和肝脏中的这种补救途径,并且这种抑制作用可通过同时给予别嘌呤醇来克服。一种可能对腺嘌呤免疫抑制活性有贡献的代谢产物可能是2 - 羟基腺嘌呤,因为它是由腺嘌呤经黄嘌呤氧化酶催化氧化产生的,抑制次黄嘌呤 - 鸟嘌呤磷酸核糖转移酶会产生与腺嘌呤相似的肾毒性并且具有免疫抑制作用。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验